SEL-212
Selecta Biosciences
[]
$selb selecta biosciences announces presentation of data from phase 3 dissolve program of sel-212 in chronic refractory gout during late-breaking session at the eular 2023 european congress of rheumatology 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities